FDA Retains Personal Touch In Monitoring Drug Promotions
This article was originally published in The Pink Sheet Daily
Based on a sales rep’s comments overheard at a pharmacist meeting, FDA warns Ortho-McNeil-Janssen about making unsubstantiated claims for pain killer Nucynta. The general pain relief claim granted the drug does not qualify it for use in the chronic pain condition discussed by the sales rep, FDA says.
You may also be interested in...
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
The company plans a push for the extended release formulation of its opioid medication.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.